ArticleEnvironmental health : a global access science source2026
Associations of prenatal exposure to per- and polyfluoroalkyl substances (PFAS) and childhood vaccine-induced immunity.
Article in Environmental health : a global access science source, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPlasma per- and polyfluoroalkyl substances (PFAS) are associated with immune dysfunction, including childhood antibody response. We evaluated whether first trimester maternal plasma PFAS concentrations are associated with mid-childhood MMR (measles, mumps, rubella) and DTaP (diphtheria, tetanus, pertussis) antibody titers.
methodsWe measured six PFAS (EtFOSSA, MeFOSSA, PFHxS, PFNA, PFOA, PFOS) in first trimester plasma from participants in the longitudinal Project Viva cohort, recruited 1999-2002 in eastern Massachusetts. We measured mid-childhood plasma MMR and DTaP antibody titers. We restricted the analytical sample to children fully vaccinated, according to 2007 United States Center for Disease Control guidelines and used covariate-adjusted quantile g-computation and regression analyses to estimate associations (n = 333-416).
resultsMedian [interquartile range (IQR)] age at antibody titer blood draw was 7.7 years (7.4, 8.4), and children received their most recent MMR or DTaP dose at median (IQR) 4.3 years (4.1, 5.0). The PFAS mixture was associated with lower antibody titers, except for measles, although none of the associations reached statistical significance. A one unit (ng/mL) increase in EtFOSSA was associated with higher measles antibody titers [β = 0.02, 95% confidence interval (CI) = 0.01, 0.04 antibody (Ab) index]. A one ng/mL increase in MeFOSSA was associated with - 6.8% (95% CI: -11.9, -1.3) lower pertussis antibody titers. There was evidence of effect modification by infant sex for prenatal PFOS and childhood pertussis antibody titers, with higher prenatal PFOS associated with lower antibody titers in females and higher in males, although neither association reached statistical significance.
conclusionsWhile the prenatal PFAS mixture was not significantly associated with childhood antibody titers in our cohort, we observed individual associations between EtFOSSA and higher measles antibody titers and MeFOSSA and lower pertussis antibody titers. Overall, we found limited evidence of associations between first trimester plasma PFAS and mid-childhood antibody titers in our cohort.
trial registrationClinical trial number: not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.